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Abstract
Gene transfer into B cells by lentivectors can provide an alternative approach to managing B lymphocyte ma-
lignancies and autoreactive B cell-mediated autoimmune diseases. These pathogenic B cell populations can be
distinguished by their surface expression of monospecific immunoglobulin. Development of a novel vector sys-
tem to deliver genes to these specific B cells could improve the safety and efficacy of gene therapy. We have
developed an efficient method to target lentivectors to monospecific immunoglobulin-expressing cells in vitro
and in vivo. We were able to incorporate a model antigen CD20 and a fusogenic protein derived from the Sind-
bis virus as two distinct molecules into the lentiviral surface. This engineered vector could specifically bind to
cells expressing surface immunoglobulin recognizing CD20 (CD20), resulting in efficient transduction of 
target cells in a cognate antigen-dependent manner in vitro, and in vivo in a xenografted tumor model. Tumor
suppression was observed in vivo, using the engineered lentivector to deliver a suicide gene to a xenografted
tumor expressing CD20. These results show the feasibility of engineering lentivectors to target immuno-
globulin-specific cells to deliver a therapeutic effect. Such targeting lentivectors also could potentially be used
to genetically mark antigen-specific B cells in vivo to study their B cell biology.
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Introduction
GENETIC REARRANGEMENT in B cells allows for the immensediversity of immunoglobulin. Individual B cell clones
differ from one another because of the variable sequences
within the antigen-binding site of the expressed immuno-
globulin (Buhl et al., 2002). Thus, surface immunoglobulin
can serve as a unique molecular determinant to differentiate
between clonal populations of B cells that can be targeted for
gene therapy delivering either a toxic gene to eliminate spe-
cific B cells, or modulating genes to enhance the function of
specific B cell populations. In fact, targeting specific im-
munoglobulin on B cells by protein-based delivery of either
unconjugated or conjugated anti-idiotypic antibodies has
been explored clinically to treat autoimmune B cells as well
as cancerous B cells (Rankin et al., 1985; Maloney et al., 1992;
Davis et al., 1998). Unconjugated anti-idiotypic antibodies
could cross-link surface immunoglobulin to initiate tyrosine
kinase signaling, resulting in stimulation of B cell apoptosis
(Vuist et al., 1994; Reff et al., 2002). Conjugation with toxins
could be used to further increase the toxic effects of anti-id-
iotypic antibodies (Reff et al., 2002).
Despite considerable progress in treating malignancies of
the hematolymphoid system, new treatment modalities are
required to treat patients more efficaciously and to target
malignant cells more accurately. In addition, some types of
B cell malignancies remain refractory to current treatment
regimens (Moskowitz, 2006). Thus, the development of novel
approaches, such as gene therapy, could contribute to the
ability to manage these diseases (Wierda and Kipps, 2000).
Lentivectors represent one of the most effective delivery ve-
hicles for transferring genes to B cells, because of their abil-
ity to transduce not only highly proliferative cells but also
quiescent cells and poorly proliferative cells such as those of
an indolent B cell neoplasm, for example, B cell chronic lym-
phocytic leukemia (Bovia et al., 2003; Janssens et al., 2003). In
the context of successful gene transfer into B cell neoplasms,
the transduction of precursor B-lymphoblastic leukemia cells
with lentiviral vectors to deliver cytokine stimulator, gran-
ulocyte-macrophage colony-stimulating factor (GM-CSF),
along with an immune-modulating molecule, CD80, has
been shown to elicit marked antileukemia immune re-
sponses, indicating the potential use of these vectors for
treating B cell tumors (Stripecke et al., 2000).
Most investigations using lentiviral vectors to deliver
genes to B cells focus on using ecotropic, amphotropic, or
vesicular stomatitis virus glycoprotein (VSVG) to envelope
human immunodeficiency virus (HIV)-derived lentiviral
vectors (Janssens et al., 2003). Because of the broad tropisms
of these pseudotyped vectors, prepurification of B cells in
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vitro, using B cell-specific markers such as CD19, is required
before transduction. The development of methods to direct
lentivectors to B cells to achieve cell type-specific transduc-
tion could enable in vivo delivery of genes to B cells. Al-
though few attempts have been made to engineer lentivec-
tors to achieve B cell-specific transduction (Mailly et al.,
2006), several efforts have been reported to incorporate B
cell-specific promoters/enhancers into lentivectors to
achieve B cell-lineage-specific expression of transgenes (Lo-
gan et al., 2002; Lutzko et al., 2003; Moreau et al., 2004).
As opposed to transcriptional targeting, we were inter-
ested in developing transductional targeting of lentivectors.
Various strategies have been attempted to direct gam-
maretroviral and lentiviral vectors to transduce specific cell
types (Lavillette et al., 2001; Sandrin et al., 2003; Verhoeyen
and Cosset, 2004; Yu and Schaffer, 2005). We have previously
reported a method to target lentivectors to B cells via CD20
(Yang et al., 2006). The method involves the incorporation of
a surface antibody specific to CD20 and a fusogenic protein
as two distinct molecules into the lentiviral surface. We have
shown that this targeting method allows for efficient and
specific delivery of genes to human B cells in vitro and in vivo
(Yang et al., 2006). In this paper, we engineer lentivectors ca-
pable of specifically transducing immunoglobulin-specific
cells. Using anti-CD20 (CD20) surface immunoglobulin as
a model target, we demonstrate that targeting lentivectors
displaying a cognate antigen and a fusogenic protein can de-
liver genes to cells expressing specific surface immunoglob-
ulin both in vitro and in vivo with remarkable specificity and
efficiency. This result also expands our targeting methodol-
ogy and presents a first example of targeting lentivectors to
immunoglobulin-specific cells.
Materials and Methods
Mice
Nonobese diabetic/severe combined immunodeficient
(NOD/SCID) mice (Jackson Laboratory, Bar Harbor, ME)
were maintained in the animal facility of the University of
Southern California (Los Angeles, CA) and cared for in ac-
cordance with institutional regulations. Treated mice were
maintained on a mixed antibiotic (sulfamethoxazole and
trimethoprim oral suspension; Hi-Tech Pharmacal, Ami-
tyville, NY).
Antibodies and flow cytometric analysis
The antibodies used in this study were phycoerythrin–
cyanine 5 (PE–Cy5)-conjugated anti-human CD20, PE–Cy5-
conjugated anti-human IgG, streptavidin–PE (all from BD
Biosciences, San Jose, CA), and biotin-conjugated anti-
hemagglutinin (HA) (Miltenyi Biotec, Bergisch Gladbach,
Germany). Flow cytometric analysis was performed with a
FACScan (BD Biosciences) and analyzed with FlowJo soft-
ware (Tree Star, Ashland, OR).
Lentivector plasmids
Lentivector plasmids used in this study were FUGW (Lois
et al., 2002), FUW, FUWLuc, and FUWSR39tk. FUW is a self-
inactivating third-generation lentivector. To make FUWLuc
and FUWSR39tk, firefly luciferase cDNA amplified from
pGL4.12Luc2P (Promega, Madison, WI) or SR39tk (Black et
al., 2001), respectively, was cloned downstream of the hu-
man ubiquitin-C promoter in the lentivector plasmid FUW.
Viral vector production
Human CD20 cDNA was cloned downstream of the cy-
tomegalovirus (CMV) promoter in pcDNA3 (Invitrogen,
Carlsbad, CA) to create pCD20. Lentivectors were gener-
ated by calcium phosphate precipitation transfection of
293T cells. 293T cells were transfected with the appropri-
ate lentivector plasmid (5 g), together with 2.5 g each
of pCD20, pSINmu (Yang et al., 2006), and the packaging
vector plasmids pMDLg/pRRE and pRSV-Rev (Dull et al.,
1998) when 80% confluent in 6-cm culture dishes. The vi-
ral supernatants were harvested 36 and 48 hr after trans-
fection and filtered through a 0.45-m pore size filter (Nal-
gene, Lima, OH). Titering was done by serial dilution of
the virus on 293T or 293T/CD20 cells with green fluo-
rescent protein (GFP)-expressing virus. Flow cytometry
was used to determine the linear range of infection as mea-
sured by GFP expression. For animal experiments, viral
vectors were concentrated by ultracentrifugation as de-
scribed previously (Yang et al., 2006).
Cell line construction
To construct cell lines expressing CD20-specific surface
immunoglobulin, we amplified cDNAs of the light chain
(CD20L) and the heavy chain (CD20H) of mouse–human
chimeric antibody (clone 2H7) from plasmid pCD20 (Yang
et al., 2006) and cloned them into FUW to generate
FUWCD20L and FUWCD20H. The cDNAs of human B
cell coreceptor, Ig and Ig, were cloned into FUW to yield
FUWIg and FUWIg. VSVG-pseudotyped viruses were
prepared for FUWCD20L, FUWCD20H, FUWIg, and
FUWIg. These viruses were used to cotransduce target cells.
After a few passages, the resulting cells were stained with
anti-human IgG1 antibody and subjected to cell sorting to
obtain a uniform population of CD20 cells designated
293T/CD20 or Jurkat/CD20. To make Jurkat/CD20Luc,
FUWLuc was pseudotyped with VSVG and used to trans-
duce Jurkat/CD20 cells.
Targeted transduction of cell lines in vitro
293T/CD20, 293T, Jurkat/CD20, or Jurkat cells (0.1 
106) were plated with 2 ml of viral supernatant in a 24-well
tissue culture dish (BD Falcon; BD Biosciences). Cells and su-
pernatant were incubated for 8 hr at 37°C, 5% CO2. Cells
were then cultured for 4 days in fresh medium at 37°C, 5%
CO2. The percentage of GFP cells was determined by flow
cytometry.
Effects of soluble antibody and NH4Cl on 
viral transduction
293T/CD20 cells (0.1  106) and 1 ml of viral supernatant
(FUGW/CD20SINmu) were coincubated in the presence
of soluble anti-human CD20 (clone 2H7; BD Biosciences), an
isotype control [IgG2b(); BD Biosciences], or NH4Cl (Fisher
Scientific, Waltham, MA). The medium was replaced 8 hr
later with fresh medium and incubated for another 4 days
at 37°C, 5% CO2. GFP expression was analyzed by flow cy-
tometry.
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Imaging for virus and viral cell binding
For labeling CD20 expression on the cell surface, 293T
and 293T/CD20 cells preincubated in a 35-mm glass-bot-
tom culture dish (MatTek, Ashland, MA) were fixed with
4% formaldehyde and immunostained with Alexa Fluor
594-labeled goat anti-human IgG (Invitrogen). These sam-
ples were also treated by 4,6-diamidino-2-phenylindole
(DAPI) nuclear staining. For detection of individual viral
particles, fresh viral supernatants were overlaid on polyly-
sine-coated coverslips and centrifuged at 3700  g at 4°C
for 2 hr. The coverslips were rinsed with cold phosphate-
buffered saline (PBS) twice, and adherent virus was im-
munostained with Alexa Fluor 647 anti-human CD20 (Bi-
olegend, San Diego, CA) and anti-HA–biotin (Miltenyi
Biotec) followed by secondary staining with Texas
red–streptavidin (Zymed Laboratories, South San Fran-
cisco, CA). The coverslips were then mounted in VEC-
TASHIELD (Vector Laboratories, Burlingame, CA). For
imaging viral cell binding, 5  105 cells were seeded into a
35-mm glass-bottom culture dish and grown at 37°C
overnight. The seeded cells were rinsed with cold PBS twice
and incubated with concentrated virus for 1 hr at 4°C to al-
low binding but inhibit endocytosis. Cells were washed
with cold PBS to remove unbound virus, fixed, and then
imaged in PBS. Fluorescence images were taken with a
Zeiss LSM 510 laser scanning confocal microscope (Carl
Zeiss, Oberkochen, Germany). A Plan-Apochromat 63/
1.4 oil immersion objective was used for imaging. 
Images were analyzed with the use of Zeiss LSM Image
Browser software.
Targeted transduction of cell lines in vivo
Mice were anesthetized with 2.5% isoflurane (Abbott An-
imal Health, Abbott Park, IL) and injected subcutaneously
via the right flank with 10  106 Jurkat/CD20 cells. Eight
hours later the mice were injected subcutaneously via both
flanks with concentrated lentivector expressing firefly lucif-
erase (FUWLuc/CD20SINmu or FUWLuc/VSVG). To an-
alyze targeting efficiency, mice were anesthetized and 3 mg
of D-luciferin (Xenogen/Caliper Life Sciences, Hopkinton,
MA) in PBS was injected intraperitoneally. After 4 min, the
mice were imaged with an IVIS 200 system (Xenogen/
Caliper Life Sciences). Images were analyzed with Living Im-
age 2.50.1 software (Xenogen/Caliper Life Sciences). This ex-
periment was performed in triplicate.
Suicide gene delivery in vivo
Mice were anesthetized and injected subcutaneously via
the right flank with 5  106 Jurkat/CD20Luc cells. Eight
hours later the mice were injected subcutaneously with con-
centrated lentivector (multiplicity of infection [MOI] of 10)
expressing herpes simplex virus-1 thymidine kinase mutant
SR39tk (FUWSR39tk/CD20SINmu or FUWSR39tk/VSVG)
or no virus as a control on the right flank. On days 7 through
12, mice were injected intraperitoneally daily with the pro-
drug ganciclovir (GCV, 50 mg/kg; Sigma-Aldrich, St. Louis,
MO). To analyze tumor size, mice were imaged with the IVIS
200 imaging system as described previously. This experi-
ment was performed in triplicate.
Results
General targeting scheme and design of a functional
lentivector envelope
The two necessary functions of the lentiviral envelope pro-
tein include binding to the host cell and fusion of the viral
membrane with the cell membrane to release the contents of
the lentivirus into the cytoplasm (Dimitrov, 2004). By sepa-
rating these functions into two separate proteins on a gam-
maretroviral or lentiviral surface, cell-specific targeting can
be achieved while maintaining viral titers (Lin et al., 2001;
Chandrashekran et al., 2004; Yang et al., 2006). There are sev-
eral features to consider in order to create an effective tar-
geting lentiviral particle by this strategy. First, the binding
of the lentivectors to the cell should induce endocytosis, and
must not interfere with fusion. Second, the fusion molecule
should be incorporated into the surface of the lentivector,
should not interfere with binding, and should induce fusion
at low pH. We set out to test whether this general method
could be extended to target B cells expressing a specific sur-
face immunoglobulin. We chose surface immunoglobulin
specific to CD20 as the molecular target and designed an 
experiment to evaluate whether CD20 antigen could be in-
corporated on the viral surface to target cells expressing 
its cognate CD20 surface immunoglobulin (Fig. 1). Im-
munoglobulins on B cells are known to endocytose when
bound to an antigen, an anti-idiotypic antibody, or an anti-
immunoglobulin antibody (Drake et al., 1989), making them
a good target for lentivectors in accordance with the intended
targeting method. For fusion, we chose the glycoprotein de-
rived from Sindbis virus (denoted as SIN), which has been
shown to be able to efficiently pseudotype HIV-1-derived
lentiviral vectors. SIN contains two transmembrane proteins
(E1, responsible for fusion; and E2, responsible for binding),
which form a heterodimer when displayed on the viral sur-
face (Phinney et al., 2000). By making mutations in the E2
protein to inactivate the receptor-binding sites, we and other
have shown that SIN can be engineered into a binding-defi-
cient but fusion-functional form (termed SINmu) (Morizono
et al., 2005; Yang et al., 2006).
Preparation of recombinant lentivectors
To produce the recombinant lentivectors, 293T cells were
transiently cotransfected by the standard calcium phosphate
method (Pear et al., 1993) with a self-inactivating and repli-
cation-incompetent lentiviral backbone that contains a hu-
man ubiquitin-C promoter driving the expression of a GFP
reporter gene, FUGW (Fig. 2A) (Lois et al., 2002); plasmids
encoding viral gag, pol, and rev genes; the plasmid encoding
human CD20 protein (denoted as pCD20); and the plasmid
encoding the fusogenic protein SINmu (denoted as
pSINmu). The resultant viral vector from these transfected
cells was designated FUGW/CD20SINmu. Transfection
without the plasmid encoding either CD20 or SINmu was
performed to generate viral vectors FUGW/SINmu and
FUGW/CD20, respectively, which were used as controls. As
a positive control we generated a lentivector pseudotyped
with VSVG and designated it FUGW/VSVG. Virus-produc-
ing cells were analyzed 3 days posttransfection by fluores-
cence-activated cell sorting (FACS) analysis (Fig. 2B and C).
GFP expression was observed in all transfected cells (Fig.
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FIG. 2. Coexpression of binding molecule
CD20, and fusogenic molecule SINmu, on
the surface of virus-producing cells. 293T
cells were transiently transfected with plas-
mids encoding lentivector FUGW, binding
protein CD20, and fusogen SINmu, along
with other standard packaging plasmids.
Three days later, the transfected cells were
detected with CD20 antibody to stain for
the binding protein and anti-HA tag to stain
for the fusogen. (A) Schematic representa-
tion of the lentiviral backbone FUGW. Ubi,
human ubiquitin-C promoter; EGFP, en-
hanced green fluorescent protein; WRE,
woodchuck regulatory element; U3,
deleted U3 region that results in the tran-
scriptional inactivation of the integrated vi-
ral LTR promoter. (B) Flow cytometric anal-
ysis of GFP expression in packaging cells.
Shaded areas, cells without exposure to
virus; solid line, cells exposed to the indi-
cated viral vector. (C) Gating on GFP-posi-
tive cells; coexpression of CD20 and SINmu
is shown.
FIG. 1. Schematic diagram of the general targeting strategy used for this study. A lentivector is engineered to codisplay
a binding determinant (CD20 antigen) and a fusogenic protein (SINmu). Specific binding of CD20 on the viral surface to
the surface CD20 antibody expressed on the target cells induces endocytosis into the endosomal compartment. In the en-
dosomal compartment, low pH triggers conformational changes of the pH-sensitive fusogen SINmu into a fusion-active
form. The activated SINmu then mediates the fusion of viral and endosomal membrane to empty the viral capsid into the
cytosol.
2B), indicating the presence of lentiviral backbone in virus-
producing cells. When we gated on GFP cells, we found
that approximately 8% of 293T cells coexpressed CD20 and
SINmu, which presumably were able to produce FUGW/
CD20SINmu (Fig. 2C). The apparently low percentage of
coexpression is partially due to the insensitivity of anti-CD20
staining antibody, which can detect only highly expressed
CD20.
Coincorporation of fusogen and binding protein 
into lentivectors
Because both binding and fusion are required for lentivec-
tors to productively transduce target cells, it was important
to investigate whether the engineered viral particles express
both CD20 and SINmu in a single virion. We designed a con-
focal imaging experiment to examine this question. We con-
structed a plasmid that expresses GFP fused to the N termi-
nus of HIV-1 Vpr (designated as GFP–Vpr). It has been
shown that GFP–Vpr was incorporated into the virion when
the GFP–Vpr plasmid was supplied in trans during viral
preparation; the resulting virus was labeled by GFP and
could be detected by green fluorescence (McDonald et al.,
2002). We prepared GFP-marked recombinant viral vector
FUW-GFPvpr/CD20SINmu under similar transfection
conditions as were used to make FUGW/CD20SINmu, ex-
cept that the lentiviral backbone FUW lacking the GFP trans-
gene replaced FUGW, and an additional plasmid encoding
GFP–Vpr was used. The resultant viral supernatant was ex-
posed to a clean glass coverslip. Costaining experiments
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FIG. 3. Confocal imaging of engineered lentiviral particles. Viral supernatant collected from virus-producing cells trans-
fected with GFP–Vpr, CD20, SINmu, lentiviral backbone FUW, and other necessary constructs was deposited on a cover-
slip precoated with polylysine by centrifugation. The resultant coverslip was rinsed with PBS and stained for CD20 with
an Alexa Fluor 647-conjugated anti-human CD20 antibody (blue) and for SINmu with a biotinylated anti-HA tag antibody
and Texas red-conjugated streptavidin (red). GFP-positive particles that had both CD20 and SINmu appeared to be white
after merging. Viral particles were also stained with a mouse anti-p24 antibody and Texas red-conjugated anti-mouse an-
tibody. Scale bars: 2 m.
showed that ?40% of GFP-marked viral particles were posi-
tive for both CD20 and SINmu (Fig. 3, top). The colocaliza-
tion of GFP–Vpr, CD20, and SINmu suggested that our
method of vector preparation can produce a good fraction
of viral particles displaying both binding and fusogenic mol-
ecules. We further stained the GFP–Vpr-containing particles
(FUW-GFPvpr/CD20SINmu) with an anti-p24 antibody. It
showed that 80% of GFP particles were p24 (Fig. 3, bot-
tom), suggesting that the dots we detected were the true vi-
ral particles.
Binding of viral particles to specific cells
To facilitate our study of specific binding and transduc-
tion using engineered lentivectors, we made 293T and Jurkat
cell lines expressing CD20 by lentivirus-mediated trans-
duction and cell sorting (293T/CD20 cells, Fig. 4A and 
C; Jurkat/CD20 cells, Fig. 4B). Flow cytometric analysis
showed that the resultant CD20 cell lines had uniform ex-
pression of CD20 (Fig. 4A and B). We compared the human
IgG expression level between the cell lines and human pe-
ripheral blood mononuclear cells (PBMCs) and found that
Jurkat/CD20 expressed a physiologically relevant level of
human IgG (lower than the IgG expression in human B cells)
(Fig. 4B). To confirm that CD20 displayed on the viral sur-
face was able to maintain its binding specificity, we coincu-
bated the concentrated viral particles (FUW-GFPvpr/
CD20SINmu) with 293T/CD20 or 293T cells at 4°C for 1
hr. At this temperature, viral particle internalization is re-
duced. As shown in Fig. 4D, GFP-marked virions were de-
tected on the surface of 293T/CD20 cells, whereas no de-
tectable virus was seen on the surface of 293T cells. As a
control, incubation of either 293T or 293T/CD20 cells with
viral supernatants harvested from producing cells trans-
fected with plasmids devoid of the plasmid encoding
Gag/Pol resulted in no bound particles. Addition of soluble
anti-CD20 antibody was observed to reduce the number of
virions bound to 293T/CD20 cells (data not shown). Thus,
CD20 incorporated into the lentiviral particles can retain spe-
cific binding to CD20-expressing cells.
Targeted transduction of cell lines in vitro
To test the ability of the engineered recombinant lentivec-
tors to transduce only cells expressing the selected surface
immunoglobulin, the supernatants from cells transfected 
to produce FUGW/CD20SINmu, FUGW/CD20, FUGW/
SINmu, or FUGW/VSVG were harvested and incubated
with stable cell lines expressing the target immunoglobulin
(293T/CD20 and Jurkat/CD20). The parental cell lines
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FIG. 4. Confocal imaging of the engineered lentivector bound to target cells. (A) Expression of CD20 on the 293T/CD20
cell line (solid line) compared with the parental 293T cells (shaded area) analyzed by flow cytometric staining with an anti-
human IgG antibody. (B) Expression of IgG on the Jurkat/CD20 cell line (green) compared with the indicated cells (Ju-
rkat [red], 293T/CD20 [blue], or human peripheral blood mononuclear cells [PBMCs] [orange]). (C) 293T/CD20 cell line
expressing CD20. The nuclei of fixed 293T and 293T/CD20 cells were labeled with DAPI. Cells were subsequently stained
with Alexa Fluor 594-conjugated goat anti-human IgG antibody. Scale bars: 5 m. (D) Binding of virus to target cell.
293T/CD20 and 293T cells were incubated at 4°C with virus harvested from producing cells transfected with the plas-
mids necessary to produce FUW-GFPvpr/CD20SINmu (labeled as “ gag/pol”). Cells incubated with viral supernatants
harvested from producing cells transfected with all the plasmids expect for gag/pol (labeled as “– gag/pol”) were included
as a control. GFP-positive viral particles are shown in green. Scale bars: 5 m.
(293T and Jurkat), negative for expression of the target anti-
body, were used as controls. Four days posttransduction,
GFP expression, which constituted a sign of positive trans-
duction, was analyzed by flow cytometry. Figure 5 shows
the result of targeted transduction in vitro. A major peak shift,
an indication of GFP expression, was observed for all cells
exposed to the positive control lentivector (FUGW/VSVG).
In contrast, transduction of targeting lentivector FUGW/
CD20SINmu resulted in significant GFP expression only in
CD20-expressing cells (Fig. 5); approximately 79.5% of
293T/CD20 cells and 10.2% of Jurkat/CD20 cells were
GFP. As controls for the role of the fusogen and binding
protein in transduction, lentivectors displaying only the
binding protein (CD20) showed no transduction for all cell
lines tested, and lentivectors displaying only the fusogen
(SINmu) showed low background transduction. CD20-neg-
ative cells transduced with FUGW/CD20SINmu yielded
only background GFP expression, confirming that the tar-
geted transduction was CD20 dependent. Titering on
293T/CD20 cells showed that the specific titer of fresh, un-
concentrated lentivector FUGW/CD20SINmu was ap-
proximately 5  106 transduction units (TU)/ml. We ob-
served that the specific transduction of Jurkat/CD20 cells
was significantly lower than that of 293T/CD20 cells. This
could be due to the lower expression of CD20 on the sur-
face of the Jurkat/CD20 cell line. Primary peripheral blood
B cell IgG expression was found to be higher than the level
of IgG expression on Jurkat/CD20 cells but less than the
expression of IgG on 293T/CD20 cells (Fig. 4B). It is also
possible that different intracellular trafficking, sorting, and
endosome properties between these two cell lines on specific
binding of FUGW/CD20SINmu could contribute to the
different levels of transduction efficiency.
Binding molecule necessary for targeted transduction
To further test whether the specific interaction between
CD20 on the lentiviral surface and CD20 on the surface of
the target cells mediated the observed targeted transduction
of FUGW/CD20SINmu, soluble CD20 antibody was
added at various concentrations to the virus–cell mixture
during transduction. The soluble antibody could compete
with the binding of the viral vector to the target cells,
293T/CD20, therefore blocking the viral transduction. An
isotype control antibody was also used as a negative control.
As expected, Fig. 5B shows that CD20 antibody concentra-
tion negatively correlated with targeted transduction,
whereas no correlation was observed between the amount
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FIG. 5. In vitro-targeted transduction of CD20-expressing cells. (A) Cell lines expressing CD20 (293T/CD20 and Ju-
rkat/CD20; 2  105) were transduced with 2 ml of fresh, unconcentrated FUGW/CD20SINmu, FUGW/SINmu,
FUGW/CD20, FUGW/VSVG, or no virus (as a negative control). Parental cell lines lacking expression of CD20 were in-
cluded as controls. GFP expression was analyzed by flow cytometry. The shaded area represents untransduced cells (with-
out exposure to the viral vector) and the solid line represents transduced cells. (B and C) 293T were seeded at 0.1  106
cells per well in a 24-well dish. FUGW/CD20SINmu (1 ml) was added to each well. (B) Effect of addition of soluble CD20
antibody on targeted transduction. Either CD20 antibody or an isotype control was added to the wells during transduc-
tion at the listed concentrations. Eight hours later, the medium was replaced with fresh medium and the cells were allowed
to grow for 4 days. Cells were then analyzed for GFP expression by flow cytometry. (C) Effect of neutralizing agent, NH4Cl,
on transduction. The indicated concentration of NH4Cl was added to the wells during transduction. Eight hours later, the
medium was replaced with fresh medium and the cells were allowed to grow for 4 days. Cells were analyzed for GFP ex-
pression by flow cytometry.
of isotype control antibody and transduction efficiency. This
verified that binding of viral CD20 to cell surface CD20 is
necessary for specific transduction.
pH change necessary for targeted transduction
Envelope glycoprotein derived from Sindbis virus is acti-
vated by the acidic pH within the lumen of endosomes to al-
low fusion of the viral particle to the host cell’s endosomal
membrane (Glomb-Reinmund and Kielian, 1998). This fusion
allows the viral particle to release its contents into the cell’s
cytosol. To test whether the drop in pH was necessary to
trigger SINmu to mediate fusion, we added ammonium chlo-
ride (NH4Cl) at various concentrations into an incubation
mixture of 293T/CD20 cells and lentivector FUGW/
CD20SINmu; NH4Cl could raise the pH to neutralize the
acidic endosomal compartments. Figure 5C shows a signifi-
cant decrease in transduction with the addition of NH4Cl,
suggesting that the lentiviral vector displaying pH-sensitive
fusogen SINmu relies on the low pH within the endosome
to mediate fusion to achieve targeted transduction.
Targeted transduction in vivo
We used NOD/SCID immunocompromised mice to ex-
amine the ability of the engineered lentivector to specifically
transduce target cells in vivo. In addition, we also compared
the efficiency of the targeting lentivector against a nontar-
geting VSVG-pseudotyped lentivector to transduce tumors
in vivo. On the right flank of each mouse, 10  106 tumor
cells (Jurkat/CD20) were injected subcutaneously as a tar-
get for the viral vector. The dorsal left side of the mice re-
ceived no tumor cells, which was used as a control. A non-
invasive bioluminescence imaging assay that employed a
firefly luciferase-bearing lentiviral vector, FUWLuc (Fig. 6A),
was used to monitor targeted transduction. We injected
FUWLuc bearing CD20 and SINmu subcutaneously 8 hr af-
ter tumor cell inoculation. Three mice received 100  106 TU
(MOI of 10) of the targeting virus (FUWLuc/CD20SINmu)
in both the right side, in the same area where the target cells
were injected, and in the left side, bearing no tumor (Fig. 6B).
To compare the targeting virus with a ubiquitously infec-
tious virus, mice were injected at MOIs of 10, 20, or 50 with
VSVG-pseudotyped lentivector. Six days after injection of
the viral vector, the substrate for firefly luciferase (D-lu-
ciferin) was injected intraperitoneally into the mice and im-
ages of light emission from anesthetized mice were obtained
with the IVIS 200 system. For the mice that received the tar-
geting vector FUWLuc/CD20SINmu, we observed lucifer-
ase activity predominantly in the area implanted with tumor
cells (right side), representing the success of targeted viral
vector transduction of tumor cells expressing CD20 in vivo
(Fig. 6C, far right). The mice that received targeting virus at
an MOI of 10 had a luminescence level on the tumor side
that was comparable to that of the mice receiving nontar-
geting FUWLuc/VSVG at an MOI of 50 (Fig. 6C). As com-
pared with FUWLuc/VSVG, the background luminescence
on the left side, bearing no tumor cells, was significantly less
for targeting vector FUWLuc/CD20SINmu, indicating the
significant specificity of our engineered lentivector.
Targeted suicide gene therapy in vivo
To test the potentially therapeutic role of our targeting sys-
tem, we used targeting vector to deliver a suicide gene, en-
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FIG. 6. Targeted transduction of Jurkat/CD20 cells in vivo. (A) Schematic representation of lentivector FUWLuc ex-
pressing firefly luciferase. Luc, firefly luciferase; Ubi, WRE, and U3 are as described in Fig. 2A. (B) Jurkat/CD20 cells
(10  106) were injected subcutaneously into the dorsal right side of NOD/SCID-HLA mice. Eight hours later, concentrated
FUWLuc/CD20SINmu, FUWLuc/VSVG, or no virus (as a control) was injected subcutaneously into both the right and
left sides of the mice. Six days later, mice were injected with 3 mg of D-luciferin and imaged with an IVIS 200 system. (C)
Top: Image of whole mice. p/s/cm2/sr, photons/sec/cm2/steradian. Bottom: Quantification of luminescence signal after
gating on the injection site. Gray columns, signal from the left side of the mice; solid columns, signal from the right side of
the mice. p/s, photons/sec. The average signal is shown for each group, consisting of three mice. Error bars represent the
standard deviation. p Values were calculated by t test.
coding herpes simplex virus type 1 thymidine kinase (HSV1-
TK), to xenografted tumors in an immunocompromised
mouse model. The cells transduced to express HSV1-TK can
be deleted by treatment with the prodrug GCV, which is
transformed into a toxic metabolite form by HSV1-TK (Blu-
menthal et al., 2007). Suicide gene therapy based on HSV1-
TK has been evaluated clinically by in situ injection of gam-
maretroviral vectors into solid tumors (Ram et al., 1997; Satoh
et al., 2005). Targeted delivery of HSV1-TK could potentially
improve the safety and efficacy of the therapy. We con-
structed a lentivector encoding a mutant form of HSV1-TK,
termed SR39tk, which has been shown to be more reactive
toward the GCV substrate and therefore has enhanced abil-
ity to kill tumor cells (Black et al., 2001). The resulting vec-
tor was designated FUWSR39tk (Fig. 7A). Tumor cells bear-
ing surface CD20 (Jurkat/CD20) were first marked in vitro
by transduction with the lentivector FUWLuc to express fire-
fly luciferase (designated as Jurkat/CD20Luc cells). Figure
7B shows a schematic of the experiment. First, Jurkat/
CD20Luc cells (5  106) were injected subcutaneously into
the right flank of each mouse. Because the xenografted tu-
mor stably expressed firefly luciferase, the relative size and
kinetic growth of the tumor could be visualized by imaging
the living animals. Eight hours after injecting Jurkat/
CD20Luc cells, 10 MOI of FUWSR39tk/CD20SINmu or
FUWSR39tk/VSVG was injected subcutaneously into the
same area as the initial tumor inoculation; no viral vector in-
jection was included as a control. From day 7 to day 12, se-
lected mice were treated daily with an intraperitoneal injec-
tion of the prodrug GCV at 50 mg/kg. Mice were imaged
throughout the process to chart the effect of each step on tu-
mor growth (Fig. 7C and D). Growth of the tumor before
GCV treatment appeared to be unaltered by transduction of
tumor cells with the SR39tk-expressing lentivector, as simi-
lar tumor growth was observed between mice injected with
FUWSR39tk/CD20SINmu and mice that received no viral
vector (Fig. 7D). The GCV treatment alone initially slowed
the growth of the tumor, but normal growth rate was re-
tained after the completion of the 5-day GCV treatment (Fig.
7C and D). The largest effect could be seen on the mice that
were injected with the targeting lentivector FUWSR39tk/
CD20SINmu or the nontargeted FUWSR39tk/VSVG and
the prodrug GCV. In these mice, tumor growth appeared to
be efficiently suppressed for more than 3 weeks, as can be
seen in Fig. 7C and D.
Discussion
Our results demonstrate that recombinant lentivector can
be engineered to target cells expressing an antigen-specific
immunoglobulin in vitro and in vivo. The general targeting
strategy is to display an antigen protein and a fusogenic pro-
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FIG. 7. Targeted suicide gene therapy to Jurkat/CD20 in vivo. (A) Schematic representation of transfer lentiviral vector
FUWSR39tk expressing SR39tk: a mutant form of the herpes simplex virus type 1 thymidine kinase. Ubi, WRE, and U3
are described in Fig. 2A. (B–D) Jurkat/CD20Luc cells (5  106) were injected subcutaneously into the right flank of 
NODSCID-HLA mice; one mouse did not receive the treatment as a control. Eight hours later, the lentivector
(FUWTK/CD20SINmu or FUWSR39tk/VSVG) was injected at the area implanted with tumor cells. During days 7 to 12,
selected mice received intraperitoneal injection of GCV prodrug. (B) Experimental scheme. (C) Bioluminescence image 1
week after the completion of prodrug treatment. p/s/cm2/sr, photons/sec/cm2/steradian. (D) Time course of tumor growth
as indicated by luminescence signal measured by gating on the right flank of tumor area. p/s, photons/sec.
tein on the lentiviral surface. In the model system reported
here, the antigen protein is CD20, which is the specific anti-
gen for the surface immunoglobulin CD20, and the fuso-
genic protein is SINmu, which is a binding-deficient and fu-
sion-competent envelope protein derived from the Sindbis
virus. To generate targeting viral particles, the virus-pro-
ducing cells are transfected to express both the binding and
fusion molecules. The natural budding mechanism of the
lentivirus incorporates the surface-expressed binding and fu-
sogenic molecules on the surface of the resultant virions,
which is confirmed by fluorescence imaging of GFP–Vpr-la-
beled viral particles.
The mechanism for viral entry of the targeting virus is be-
lieved to begin with binding of CD20 to the targeted im-
munoglobulin CD20. Using confocal imaging, we could
only binding of the virus see to cells expressing CD20.
When soluble CD20 antibody was added to the cell culture
system to compete with the targeting lentivector for binding
to CD20-expressing cells, viral transduction was greatly in-
hibited. This shows that binding through the CD20 im-
munoglobulin is necessary for the targeting viral vector to
enter the cell. Binding of the immunoglobulin could induce
endocytosis. In the endosomal compartment, the drop in pH
triggers the fusion function of pH-sensitive fusogen SINmu,
as shown in an endosomal neutralization assay in which we
observed a sharp decrease in transduction with the addition
of NH4Cl.
Targeted transduction in vitro shows that the targeting
lentivector preferentially transduces cells expressing the
CD20 immunoglobulin. Whereas the viral vector carrying
only CD20 or SINmu resulted in no transduction, the
lentivector bearing both CD20 and SINmu can efficiently
transduce 293T/CD20 cells (79.5%). We further showed in
vivo targeted transduction of a xenografted Jurkat/CD20
tumor. Jurkat/CD20 cells were injected subcutaneously
into the right flank of immunocompromised mice, followed
by the injection of viral vector delivering the firefly lucifer-
ase gene into both the right and left flanks of the mice. One
week postdelivery, various concentrations of VSVG-pseudo-
typed viral vectors were compared with 10 MOI of the en-
gineered lentivector FUWLuc/CD20SINmu by measuring
bioluminescence in live animals. Fewer infectious particles
were needed for the targeting vector to achieve the same
level of expression seen in the tumors transduced with the
nontargeting VSVG-pseudotyped viral vector. We speculate
that the nonspecific binding of VSVG to multiple types of
animal tissue cells results in less viral vector reaching the tar-
get cells as compared with the targeting vector, although
more direct evidence needs to be obtained experimentally in
order to support this argument. Nevertheless, this result
highlights the advantage of developing targeted delivery ve-
hicles for in vivo gene therapy.
Previously we reported a method to engineer lentivectors
to target B cells by incorporating a membrane-bound anti-
body (CD20) and a fusogen (SINmu) into the lentiviral sur-
face (Yang et al., 2006). The resulting vectors could efficiently
transduce B cells expressing the cognate CD20 antigen. In
this study, we demonstrated that it is feasible to design a re-
ciprocal targeting strategy to direct lentivectors to deliver
therapeutic genes to cells expressing a particular im-
munoglobulin. This also constitutes the first report of effi-
cient targeting of lentivector to monospecific immunoglob-
ulin-expressing cells. Our method of incorporating a specific
antigen on the lentiviral surface is a feasible approach to tar-
geting clonal and autoreactive B cells for certain autoimmune
diseases with known antigens such as pemphigus vulgaris
and Graves’ disease (Davidson and Diamond, 2001). For
cases in which the antigen against a specific immunoglobu-
lin is unknown, we can use the previously reported method
(Yang et al., 2006) to incorporate a secondary, anti-idiotypic
antibody onto the lentiviral surface. Thus, these two meth-
ods could complement each other to provide novel ways to
achieve gene delivery to defined populations of B cells.
Delivery of modulating genes to antigen-specific B cells
could be used to tune B cell function related to a particular
antigen. For example, class switching and differentiation of
B cells can vary depending on the available cytokine con-
centration (Tarlinton, 2006). Interleukin (IL)-4 plays impor-
tant roles in driving the switch to IgG1 and further to IgE
(Snapper et al., 1988). Cytokines, such as IL-2, IL-5, and trans-
forming growth factor (TGF)-, could alter B cells to aug-
ment their production of specific IgA (McHeyzer-Williams
and McHeyzer-Williams, 2005). Delivery of these genes to
chosen B cells can alter the isotype, magnitude, and spec-
trum of antibodies secreted by antigen-specific B cells. As
genes involved in controlling the generation of memory B
cells are identified, targeted delivery of such genes to B cells
could improve the antigen-specific memory responses
(McHeyzer-Williams and McHeyzer-Williams, 2005). The
ability to genetically mark antigen-specific B cells in vivo
could provide a new way to study basic B cell biology (Ja-
cob and Baltimore, 1999; Tarlinton, 2006).
Specific delivery of a suicide gene to eliminate a disease-
associated population of B cells in cancer or in autoimmune
disease has therapeutic implications. B cell depletion has
been successfully used clinically to treat cancer and autoim-
mune diseases (Goronzy and Weyand, 2003; Edwards and
Cambridge, 2005; Martin and Chan, 2006). Most of these de-
pletion therapies target a pan-B cell marker (Martin and
Chan, 2006). One of the most successful B cell-depleting
methods to date is rituximab, an CD20 antibody (Edwards
and Cambridge, 2005). However, because rituximab recog-
nizes CD20, a widely expressed B cell marker, it is unable to
deplete only the specific subset of diseased B cells, leading
to undesirable side effects, including hypogammaglobuline-
mia (Chaiwatanatorn et al., 2003; Imashuku et al., 2004) and
increased susceptibility to infection (Wadhwa and Morrison,
2006). Targeting a more specific population of B cells by sui-
cide gene therapy could overcome some of the challenges
that rituximab faces. To test whether our system could ef-
fectively deliver a suicide gene in vivo, we set up a mouse
model with a xenografted tumor expressing firefly lucifer-
ase. By measuring the bioluminescence from firefly lucifer-
ase, we could monitor the kinetic growth of the tumor. We
found that a single-dose injection of FUWSR39tk/
CD20SINmu along with the prodrug treatment was able
to substantially suppress tumor growth. Although we clearly
showed that more cells were targeted by using the targeting
vector (Fig. 6C), we did not observe markedly improved sup-
pression of tumor growth when using the targeting vector
as opposed to the nontargeting vector (Fig. 7C and D). One
possible explanation is the known bystander effect of suicide
gene therapy (Freeman et al., 1993). Although only a small
fraction of the tumor cells was transduced to express the sui-
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cide gene, Freeman and coworkers remained able to detect
a significant reduction in tumor size after GCV treatment
(Freeman et al., 1993). An increase in the dose and frequency
of injection of targeting lentivector bearing the suicide gene
could further enhance the efficiency of tumor therapy.
A clinical trial using lentivectors to deliver antisense RNA
for anti-HIV therapy has shown no detectable adverse effects
(Levine et al., 2006), highlighting the promise of lentivectors
for gene therapy (Kohn, 2007). A general concern about the
clinical use of lentivectors is insertional mutagenesis,
sparked by the X-linked severe combined immunodeficiency
(SCID) trial in France, in which some gammaretroviral vec-
tor-treated patients developed leukemia as a result of the
outgrowth of transduced cells (Hacein-Bey-Abina et al.,
2003). Although more studies are needed to fully gauge the
oncogenesis of this third-generation lentivector system, Nal-
dini and coworker have shown in a tumor-prone mouse
model, using hematopoietic stem cell gene transfer, that
lentivectors have lower oncogenic potential (Montini et al.,
2006), which could be a major advantage as a gene transfer
vector, as opposed to gammaretroviral vectors. A suicide
gene therapy could be incorporated into the gene therapy
protocol to further increase safety by eliminating, via pro-
drug treatment, the abnormally proliferative cells that have
been marked with a suicide gene (Blumenthal et al., 2007).
Our findings suggest that engineering a gene delivery sys-
tem based on lentivectors to target antigen-specific im-
munoglobulin-expressing cells is feasible both in vitro and in
vivo, using direct intratumoral injection. It should be pointed
out that such an approach may be appropriate for clinically colo-
calized disease, such as low-stage non-Hodgkin lymphoma. Fu-
ture work will be required to validate this method for systemic
administration of lentivectors for disseminated disease.
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